Early access
Sign in
Taking people in United StatesNo phase

Studies neuroblastoma cells and tissue samples to learn more about the disease

Collects tumor, blood and bone marrow samples from people with neuroblastoma to study the cancer.

Key facts

Who runs it
New Approaches to Neuroblastoma Therapy Consortium
Where
Ann Arbor, Atlanta, Aurora, Boston, Chapel Hill, Chicago, Cincinnati, Columbus, Dallas, Fort Worth, Los Angeles, Memphis, Palo Alto, Philadelphia, San Francisco, and Seattle, United StatesSee the 16 sitesAlso in 1 other country, 1 site
Trial code
Registry title
Neuroblastoma Biology Study
Status
Recruiting
People taking part
1,000 people, planned
Started
Jul 2011
Expected to end
Dec 2099
Type of study
Observational
Record updated
23 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with high risk neuroblastoma, including those whose cancer did not respond to treatment or came back. Samples of tumour, blood and bone marrow are studied.

Age
From 31 days of age up to 99 years.
Sex
All sexes can join.
Disease stage
High risk neuroblastoma, confirmed by tumour tissue examination, or tumour cells in the bone marrow together with raised catecholamines in the urine. It can be treatment-resistant, recurrent, or without relapse.

Main reasons for not taking part

  • The record lists no exclusion criteria.

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Patients must be greater than or 31 days of age
  • Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines
  • All patients with refractory or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted
  • Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized

Who cannot take part

  • There are no exclusion criteria on this study

Where in United States

Also in 1 other country, 1 site

  • C S Mott Children's HospitalAnn Arbor, United StatesContact: Rajen Mody, MDTaking people
  • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston CampusAtlanta, United StatesContact: Kelly Goldsmith, MDTaking people
  • Children Hospital of ColoradoAurora, United StatesContact: Margaret Macy, MDTaking people
  • Children's Hospital, BostonBoston, United StatesContact: Suzanne Shusterman, MDTaking people
  • University of North CarolinaChapel Hill, United StatesContact: Araz Marachelian, MDNo longer taking part
  • University of Chicago Comer Children's HospitalChicago, United StatesContact: Ami Desai, MDTaking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Katherine Somers, MDTaking people
  • Nationwide Children's HospitalColumbus, United StatesContact: Keri Streby, MDTaking people
  • University of Texas, SouthwesternDallas, United StatesContact: Tanya Watt, MDNot yet recruiting
  • Cook Children's Medical Center - Fort WorthFort Worth, United StatesContact: Chelsee Greer, DOTaking people
  • Children's Hospital Los AngelesLos Angeles, United StatesContact: Araz Marachelian, MDTaking people
  • St. Jude Children's Research HospitalMemphis, United StatesContact: Sara Federico, MDNot yet recruiting
  • Lucille Salter Packer Children's Hospital, Stanford UniversityPalo Alto, United StatesContact: Araz Marachelian, MDNo longer taking part
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Yael Mosse, MDTaking people
  • UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, United StatesContact: Kieuhoa Vo, MDTaking people
  • Seattle Children's HospitalSeattle, United StatesContact: Mark Fluchel, MDTaking people

About the trial

What the trial wants to find out

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
N2004-05: Neuroblastoma Biology Study
Plain-language title
Studies neuroblastoma cells and tissue samples to learn more about the diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 March 2026